IP Library Granted Patent US 8,389,748
Granted Patent B2
US 8,389,748 · App. 12/762,917 · Granted Mar 5, 2013

Method for preparing prostaglandin derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,748
App. No.
12/762,917
Granted
Mar 5, 2013
Kind
B2
Abstract

Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as sole base. By carrying out the reaction using an alkali hydroxide as sole base in the reaction system, the desired prostaglandin derivative can be obtained by simple procedures and with high yield.

Claims (27)

1. A method for preparing a prostaglandin derivative of formula (A):

wherein A 1 is a hydrogen or a protecting group for a hydroxy group;

Y is —OA 2 , wherein A 2 is a hydrogen or a protecting group of a hydroxy group;

W is —R 1 -Q, wherein R 1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic, and at least one of carbon atoms in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur, Q is —CH 3 , —COCH 3 , —OH, —COOH or a functional derivative thereof; or

Y and W may both together form a group represented by the formula:

wherein R 1 ′ is a bivalent saturated or unsaturated lower to medium aliphatic hydrocarbon residue;

R 3 is a saturated or unsaturated lower to medium aliphatic hydrocarbon residue that is unsubstituted or substituted with a lower alkoxy, a lower alkanoyloxy, a cyclo(lower)alkyl, a cyclo(lower)alkyloxy, an aryl, an aryloxy, a heterocyclic or a heterocyclicoxy; a cyclo(lower)alkyl group; a cyclo(lower)alkyloxy group; an aryl group; an aryloxy group; a heterocyclic group; a heterocyclicoxy group;

X 1 and X 2 are a hydrogen, a lower alkyl group or a halogen; and

Z is ═CH— or —CH═CH—,

provided that —OA 1 and Q may together form

which comprises reacting an aldehyde represented by formula (1):

wherein Y, W and A 1 have the same meanings as above;

B is a single bond or —CH 2 —, with a 2-oxoalkyl phosphonate represented by formula (2):

wherein X 1 , X 2 and R 3 have the same meanings as above; and

R 2 is a lower alkyl group;

in a reaction solvent under the presence of a hydroxide selected from the group consisting of alkali metal hydroxide and alkaline earth metal hydroxide as sole base,

wherein at least one of X 1 and X 2 is a halogen.

2. The method according to claim 1 , wherein both X 1 and X 2 are halogen.

3. The method according to claim 1 , wherein both X 1 and X 2 are fluorine.

4. The method according to claim 1 , wherein the reaction solvent comprises approximately 0.5 to 10% water.

5. The method according to claim 1 , wherein the reaction solvent is an ether.

6. The method according to claim 1 , wherein the prostaglandin derivative is a compound represented by formula (B):

and the aldehyde is a compound represented by formula (3):

wherein A 1 , A 2 , B, R 1 , Q, X 1 , X 2 and Z have the same meanings as defined in claim 1 .

7. The method according to claim 1 , wherein the prostaglandin derivative is a compound represented by formula (C):

and the aldehyde is a compound represented by formula (4):

wherein A 1 , B, R 3 , X 1 , X 2 and Z have the same meanings as defined in claim 1 .

Assignments (8)
SECURITY INTEREST Recorded Oct 28, 2025
From: STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 072700/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 071913/0691 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →